Clinical Trial Update: Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 randomized, double-blind trial comparing erlotinib with pazopanib versus erlotinib with placebo in previously treated advanced non-small cell lung cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)
• Votrient (Pazopanib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-01-29